TWI828644B - 微管蛋白抑制劑 - Google Patents

微管蛋白抑制劑 Download PDF

Info

Publication number
TWI828644B
TWI828644B TW107143753A TW107143753A TWI828644B TW I828644 B TWI828644 B TW I828644B TW 107143753 A TW107143753 A TW 107143753A TW 107143753 A TW107143753 A TW 107143753A TW I828644 B TWI828644 B TW I828644B
Authority
TW
Taiwan
Prior art keywords
alkyl
formula
compounds
halogen
heteroaryl
Prior art date
Application number
TW107143753A
Other languages
English (en)
Chinese (zh)
Other versions
TW201930266A (zh
Inventor
雨新 林
王正琪
傑森 歐雷尼札克
潔西卡 克里斯普
理查 楚歐恩
Original Assignee
仁新醫藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 仁新醫藥股份有限公司 filed Critical 仁新醫藥股份有限公司
Publication of TW201930266A publication Critical patent/TW201930266A/zh
Application granted granted Critical
Publication of TWI828644B publication Critical patent/TWI828644B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW107143753A 2017-12-06 2018-12-05 微管蛋白抑制劑 TWI828644B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762595530P 2017-12-06 2017-12-06
US62/595,530 2017-12-06

Publications (2)

Publication Number Publication Date
TW201930266A TW201930266A (zh) 2019-08-01
TWI828644B true TWI828644B (zh) 2024-01-11

Family

ID=66658388

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107143753A TWI828644B (zh) 2017-12-06 2018-12-05 微管蛋白抑制劑

Country Status (8)

Country Link
US (3) US11040945B2 (enExample)
EP (1) EP3720436A4 (enExample)
JP (1) JP7319977B2 (enExample)
KR (1) KR20200104873A (enExample)
CN (1) CN111727042A (enExample)
AU (1) AU2018380132B2 (enExample)
TW (1) TWI828644B (enExample)
WO (1) WO2019113242A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019200683B2 (en) * 2018-02-01 2024-05-30 The University Of Sydney Anti-cancer compounds
US11472774B2 (en) 2018-02-01 2022-10-18 The University Of Sydney Anti-cancer compounds
JP7594787B2 (ja) 2018-12-07 2024-12-05 ユニバーシティ オブ メリーランド、ボルチモア 非ATP/触媒部位p38マイトジェン活性化プロテインキナーゼ阻害剤
AU2020319879A1 (en) * 2019-07-31 2022-02-03 Aclaris Therapeutics, Inc. Deuterated MK2 pathway inhibitors and methods of using the same
US20210147441A1 (en) * 2019-09-26 2021-05-20 Agency For Science, Technology And Research (A*Star) Therapeutic compounds and methods of use thereof
AU2020407664A1 (en) 2019-12-20 2022-08-18 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
CN115666566A (zh) 2020-03-27 2023-01-31 阿克拉瑞斯治疗股份有限公司 用于免疫病况的治疗的mk2途径抑制剂的口服组合物
KR102844239B1 (ko) * 2020-11-10 2025-08-08 가천대학교 산학협력단 신규한 카바졸 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
IL306101A (en) * 2021-03-23 2023-11-01 Gen1E Lifesciences Inc Naphthyl-mutated p38 alpha mitogen-activated protein kinase inhibitors
EP4333841A1 (en) 2021-05-04 2024-03-13 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868380A (en) * 1972-05-23 1975-02-25 Luigi Molteni Diphenylyl-al kanoylaminopyridines and salts thereof
WO2006060108A1 (en) * 2004-10-29 2006-06-08 Merck & Co., Inc. N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators
TWI321562B (en) * 2005-03-15 2010-03-11 4Sc Ag Novel sulphonylpyrroles
WO2016119017A1 (en) * 2015-01-30 2016-08-04 The University Of Sydney Anti-cancer compounds

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2205732A1 (de) 1972-02-08 1973-08-16 Thomae Gmbh Dr K Neue 4-(4-biphenylyl)-butensaeurederivate
AT336594B (de) 1973-08-14 1977-05-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer 3-(4- biphenylyl)-buttersaureamiden
US5196543A (en) 1989-10-17 1993-03-23 Delalande S.A. 3-aryloxazolidinone derivatives, process for their preparation and their use in therapy
CA2083048A1 (en) 1990-06-14 1991-12-15 James K. Bashkin Rna hydrolysis/cleavage
JP2969618B2 (ja) * 1995-06-27 1999-11-02 田辺製薬株式会社 ピリダジノン誘導体及びその製法
US5756507A (en) 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP3060454B2 (ja) * 1996-12-26 2000-07-10 田辺製薬株式会社 医薬組成物
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
BR0013143A (pt) 1999-08-12 2002-06-11 Pharmacia Italia Spa Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
JP4772690B2 (ja) * 2003-12-03 2011-09-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド チューブリン阻害剤
PE20060241A1 (es) 2004-05-18 2006-04-01 Schering Corp 2-quinolil-oxazoles sustituidos como inhibidores de pde4
US20070254913A1 (en) 2006-04-19 2007-11-01 Dunn Robert F Phosphodiesterase 4 inhibitors
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
JP2009185010A (ja) 2008-02-08 2009-08-20 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害剤を含有する医薬
FR2933700B1 (fr) * 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
CN102470127A (zh) 2009-08-19 2012-05-23 埃姆比特生物科学公司 联芳基化合物和其使用方法
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
CN102834380B (zh) * 2010-03-10 2015-04-01 阿斯利康公司 蛋白激酶的抑制剂
RU2576662C2 (ru) 2010-03-18 2016-03-10 Энститю Пастер Корея Противоинфекционные соединения
EP2729146B1 (en) 2011-07-08 2017-03-08 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
US20130267712A1 (en) 2012-04-02 2013-10-10 Board Of Trustees Of Northern Illinois University Aromatic ketone synthesis with amide reagents and related reactions
CN105473559B (zh) 2013-03-15 2019-05-10 南洋理工大学 用于化学转化的羰基β-碳的活化
AR098475A1 (es) 2013-11-26 2016-06-01 Bayer Cropscience Ag Compuestos pesticidas y usos
WO2016067009A1 (en) 2014-10-28 2016-05-06 Redx Pharma Plc Compounds with activity against bacteria and mycobacteria
EP3302448B1 (en) 2015-06-04 2023-10-25 Aurigene Oncology Limited Substituted heterocyclyl derivatives as cdk inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868380A (en) * 1972-05-23 1975-02-25 Luigi Molteni Diphenylyl-al kanoylaminopyridines and salts thereof
WO2006060108A1 (en) * 2004-10-29 2006-06-08 Merck & Co., Inc. N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators
TWI321562B (en) * 2005-03-15 2010-03-11 4Sc Ag Novel sulphonylpyrroles
WO2016119017A1 (en) * 2015-01-30 2016-08-04 The University Of Sydney Anti-cancer compounds

Also Published As

Publication number Publication date
US12247010B2 (en) 2025-03-11
AU2018380132A1 (en) 2020-06-18
CN111727042A (zh) 2020-09-29
AU2018380132B2 (en) 2023-11-09
JP7319977B2 (ja) 2023-08-02
AU2018380132A8 (en) 2020-07-09
US20190169127A1 (en) 2019-06-06
JP2021508318A (ja) 2021-03-04
US20220089539A1 (en) 2022-03-24
KR20200104873A (ko) 2020-09-04
US20250188035A1 (en) 2025-06-12
TW201930266A (zh) 2019-08-01
EP3720436A4 (en) 2021-06-02
US11040945B2 (en) 2021-06-22
WO2019113242A1 (en) 2019-06-13
EP3720436A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
TWI828644B (zh) 微管蛋白抑制劑
CN104981458B (zh) 组蛋白去甲基化酶抑制剂
AU2014298051B2 (en) Novel quinazolinones as bromodomain inhibitors
AU2015227454B2 (en) Functionalised and substituted indoles as anti-cancer agents
CN107698585A (zh) 杂环基化合物
US12122800B2 (en) Inhibitors of MEK kinase
WO2020035040A1 (zh) 3-芳氧基-3-五元杂芳基-丙胺类化合物及其用途
WO2013007184A1 (zh) 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用
JP6719451B2 (ja) キナゾリン誘導体
TW202342017A (zh) 用於治療與lpa受體活性相關的病狀的化合物及組合物
JP2024119825A (ja) 鎮痛化合物及びその製造方法
WO2023086417A1 (en) Compounds and methods of use thereof
CN112979638B (zh) 一种噻唑化合物及其用途
WO2025054260A1 (en) Inhibitors of mek kinase
WO2025201397A1 (en) Tead inhibitors and methods of uses thereof
WO2025007859A1 (en) Substituted thiazole compounds as cdk2/4/6 inhibitors and methods of use thereof
WO2023070076A1 (en) Compounds for cancers driven by braf mutation
TW202003450A (zh) 脂肪酸類似物及使用方法
BR112021009723A2 (pt) compostos pró-fármaco e de amida, mistura de um pró-fármaco ou de um composto, composição farmacêutica, uso de um composto ou mistura ou composição, e, método para inibir necrose, ferroptose, rip1 humana ou indicações relacionadas.
BR112021009723B1 (pt) Composto, composição farmacêutica, e, seus usos
HK1247920B (zh) 组蛋白去甲基化酶抑制剂
HK1168087A (en) Small molecule inhibitors of the pleckstrin homology domain and method for using same